Related Experiment Video
Updated: Jan 31, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
What Makes a Kinase Promiscuous for Inhibitors?
Sonya M Hanson1, George Georghiou2, Manish K Thakur2
1Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11794-8651, USA; Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065-1115, USA.
Kinase inhibitors bind multiple targets due to conserved pockets. This study reveals receptor tyrosine kinase DDR1 binds inhibitors in an inactive state, explaining its promiscuity and offering new insights into drug discovery.
Area of Science:
- Biochemistry
- Structural Biology
- Pharmacology
Background:
- ATP-competitive kinase inhibitors often exhibit promiscuity due to conserved ATP-binding pockets across kinases.
- Kinome-wide profiling data reveals a subset of kinases are disproportionately targeted by inhibitors.
Purpose of the Study:
- To investigate the structural basis for promiscuous inhibitor binding in kinases.
- To understand why certain kinases bind a higher number of inhibitors.
Main Methods:
- Clustering analysis of kinome profiling data.
- Co-crystal structure determination of DDR1 with inhibitors dasatinib and VX-680.
- Computational and biochemical assays to assess kinase conformation and stability.
Main Results:
- Identified a cluster of eight highly promiscuous kinases.
- DDR1 unexpectedly binds type I inhibitors in an inactive conformation.
- DDR1 exhibits unusual stability in this inactive conformation.
Conclusions:
- The stability of DDR1 in an inactive conformation provides a mechanistic explanation for its promiscuity with type I inhibitors.
- Phenotypic clustering offers functional insights beyond sequence homology.
- This work advances understanding of kinase inhibitor interactions and promiscuity.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Receptor Tyrosine Kinases
cAMP-dependent Protein Kinase Pathways

